Tepezza Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Tepezza Indications
Indications
Tepezza Dosage and Administration
Adult
Children
Renal Impairment
No clinically significant differences in the pharmacokinetics of teprotumumab-trbw were observed in patients with mild to moderate renal impairment.
Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of teprotumumab-trbw is unknown.
Other Modifications
Females of reproductive potential: Use effective contraception prior to initiation, during treatment, and for 6 months after the last dose.
Tepezza Contraindications
Not Applicable
Tepezza Boxed Warnings
Not Applicable
Tepezza Warnings/Precautions
Warnings/Precautions
Exacerbation of preexisting inflammatory bowel disease; if suspected, consider discontinuation. Hyperglycemia may occur; assess for elevated blood glucose, symptoms of hyperglycemia prior to infusion, monitor while on treatment. Patients with hyperglycemia or pre-existing diabetes: ensure appropriate glycemic control before and while receiving treatment. Advise females of reproductive potential to use effective contraception prior to initiation, during and for 6 months after the last dose. Pregnancy: not recommended. Nursing mothers.
Tepezza Pharmacokinetics
Elimination
Tepezza Interactions
Tepezza Adverse Reactions
Adverse Reactions
Tepezza Clinical Trials
Tepezza Note
Not Applicable